Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 20729864.
- Also identified by DOI 10.1038/nm.2199 and PMC identifier 2935926.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we identify inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease.
Medical subject headings
- Parkinson Disease
- Protein Serine-Threonine Kinases